Company Sees FY26 Revenue of $1.13B to $1.17B
Sees FY26 revenue $1.13B-$1.17B, consensus $1.15B. Sees FY26 adjusted EBITDA $88.5M-$94.1M. Lynette Walbom, the company's CFO, also stated, "We believe providing updated annual adjusted consolidated EBITDA guidance in addition to updated annual revenue and adjusted earnings per share guidance is helpful to understanding our expectations for our business and operational cash flow. This updated guidance reflects management's expectations based on 2025 performance and current operating conditions as well as the impacts of the transaction with UnitedHealth and Amedisys. Our guidance includes revenue in the range of $191.2 to $200.3 million, adjusted EBITDA in the range of $16.7 to $17.9 million, and adjusted EBITDA prior to NCI of $19.8 to $21.1 million relating to these former UnitedHealth and Amedisys assets."
Trade with 70% Backtested Accuracy
Analyst Views on PNTG
About PNTG
About the author

- Conference Participation: The Pennant Group will participate in the 2026 Oppenheimer Co. Annual Healthcare MedTech & Services Conference on March 18, 2026, where CEO Brent Guerisoli and CFO Lynette Walbom will engage in a discussion, showcasing the company's expertise and leadership in healthcare services.
- Live Webcast: The event is scheduled for 9:40 a.m. Eastern Time, with a live webcast available, allowing investors and stakeholders to stay updated on the company's latest developments, thereby enhancing transparency and communication efficiency.
- Company Background: The Pennant Group is a holding company of independent operating subsidiaries focused on providing healthcare services across the United States, emphasizing the independent management and operation of each subsidiary to ensure service quality and professionalism.
- Investor Relations: By participating in such industry conferences, the Pennant Group not only enhances its visibility in the healthcare sector but also provides potential investors with direct insights into the company's strategies and operations, further boosting market confidence.
- Strong Financial Performance: Pennant Group reported total revenue of $947.7 million for 2025, a 36.3% increase, with adjusted EBITDA at $72.5 million, reflecting successful integration of Signature Healthcare and acquisition of over 50 locations, driving significant growth.
- Quarterly Highlights: The Home Health and Hospice segment generated $233.3 million in Q4 revenue, with admissions surging 81.3%, indicating strong market demand and laying a solid foundation for future revenue growth.
- Positive Outlook: Management projects 2026 revenue between $1.13 billion and $1.17 billion, with adjusted EBITDA of $88.5 million to $94.1 million, demonstrating confidence in the integration of newly acquired operations and expected continued profit growth.
- Robust Capital Structure: The CFO noted a net debt to adjusted EBITDA ratio of 1.7x, well below the 3.25x covenant limit, and projected operating cash flows of $45 million to $55 million, indicating strong financial health.
- Significant Profit Growth: The Pennant Group reported a fourth-quarter profit of $8.64 million, translating to $0.24 per share, which marks a substantial increase from last year's $5.76 million and $0.16 per share, indicating improved profitability.
- Strong Adjusted Earnings: Excluding items, the company reported adjusted earnings of $12.16 million or $0.34 per share, suggesting that its core business performance exceeded market expectations, thereby boosting investor confidence.
- Revenue Surge: The company's revenue for the fourth quarter rose by 53.2% to $289.32 million from $188.89 million last year, reflecting rapid growth driven by strong market demand.
- Positive Market Outlook: With significant increases in both profit and revenue, the Pennant Group's competitive position in the industry is strengthened, likely attracting further investor interest and driving stock price appreciation.
- Earnings Beat: Pennant's Q4 2023 Non-GAAP EPS of $0.34 exceeded expectations by $0.02, indicating a robust enhancement in profitability that strengthens market confidence.
- Significant Revenue Growth: The fourth quarter revenue reached $289.32 million, a 53.2% year-over-year increase, surpassing market expectations by $14.12 million, reflecting strong performance amid robust market demand.
- EBITDAR and EBITDA Improvement: The full-year adjusted EBITDAR was $120.9 million, up 26.2%, while Q4 reached $35.3 million, a 41.7% increase, showcasing significant operational efficiency gains.
- Optimistic 2026 Guidance: Management anticipates total revenue for 2026 to be between $1.1336 billion and $1.1718 billion, with adjusted EPS expected between $1.26 and $1.36, demonstrating confidence in future growth and clear strategic planning.
- Earnings Release Announcement: The Pennant Group expects to issue its fourth quarter and fiscal year 2025 financial results on February 25, 2026, showcasing its operational achievements in home health, hospice, and senior living services.
- Investor Webcast: The company invites current and prospective investors to join a live webcast on February 26, 2026, at 10:00 a.m. Mountain Time, where management will discuss the financial results in detail, enhancing investor relations.
- Financial Information Access: Investors can access financial and other statistical information required by SEC Regulation G through the Investor Relations section of the Pennant Group's website, ensuring transparency and compliance.
- Company Background: The Pennant Group is a holding company with independent operating subsidiaries providing healthcare services across 17 states, emphasizing the independent management and operation of each subsidiary to ensure service quality and professionalism.








